3rd Quarter - Report

DRUG POLICY ALLIANCE for DRUG POLICY ALLIANCE

Firm
Client
Income
—
Expenses
$5,490
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Law Enforcement/Crime/Criminal Justice LAW

We urged Congress to support and co-sponsor the MORE Act (H.R. 5068). We urged Congress to support and co-sponsor the Cannabis Administration and Opportunity Act in the Senate. We urged Congress to oppose the Combating Xylazine Act(H.R. 1266/S. 545), Nitazene Control Act (H.R. 5415 /S. 3076), and STOP Nitazenes Act (H.R. 7970).

LobbyistCovered position, as disclosed
MARITZA PEREZ MEDINA —
HANNA SHARIF-KAZEMI —

Bills named: H.R. 1266 (119th), H.R. 5068 (119th), S. 545 (119th), H.R. 5415 (119th), S. 3076 (119th), H.R. 7970 (119th)

Civil Rights/Civil Liberties CIV

We urged Congress to support the RESTORE Act (H.R. 5223), a bill that would end the SNAP drug felony ban. We urged Congress to repeal the Thurmond Amendment to end housing discrimination via a bill called the Fair Future Act (H.R. 7765).

LobbyistCovered position, as disclosed
HANNA SHARIF-KAZEMI Policy Manager

Bills named: H.R. 5223 (119th), H.R. 7765 (119th)

Health Issues HCR

We urged Congress to fully fund health programs that support people struggling with addiction in Congressional spending bills (LHHS FY27 appropriations bills). We opposed the inclusion of a rider to ban overdose prevention centers in Congressional spending bills.

LobbyistCovered position, as disclosed
DANIEL FISHBEIN New —
HANNA SHARIF-KAZEMI —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.